Home > Innovation > Drug Discovery

Drug Discovery

The main focus of the ETP is to support drug discovery projects derived from CNIO research by delivering balanced and optimised lead compounds (activity, off-target selectivity and Absorption-Distribution- Metabolism-Excretion, Toxicity (ADME-Tox) properties) with demonstrated in vivo proof-of-concept (PoC) after oral administration (mechanism of action and efficacy in tumour models). The Programme’s capabilities in early drug discovery range from High-Throughput Screening (HTS) assay development, medicinal chemistry for hit generation, hit-to-lead and lead optimisation, to in vivo pharmacokinetics and PoC studies in animal models of human cancer.

In addition to full drug discovery projects, ETP offers its capabilities and skills to the CNIO Research Community and externally under contract research:

  • HTS Platform: transfer of manually developed assays (biochemical and cellular) into a high-quality HTS environment.
  • Antiproliferation combination studies in cell lines.
  • Chemical Library and Tool Compounds: library of 50K chemically diverse compounds with a focus on cancer targets, and a collection of FDA approved drugs for their ‘repositioning’ in cancer therapy.
  • Assistance in the identification of chemical tools and synthesis of non-available compounds.
  • Medicinal Chemistry (Hit generation/HtL/LO)
  • Chemical Synthesis
  • Expertise covering in vivo pharmacokinetics, pharmacokinetics/ pharmacodynamics (PK/PD) and efficacy studies.